



Docket No.: 22116-00005-US3  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re Patent Application of:  
Christine L. O'Day et al.

Application No.: 09/396,523

Confirmation No.: 7553

Filed: September 15, 1999

Art Unit: 1621

For: NOVEL POLYAMINE ANALOGUES AS  
THERAPEUTIC AND DIAGNOSTIC  
AGENTS

---

Examiner: P. G. O'Sullivan

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement, pursuant to 37 CFR 1.114(c), accompanies the Request for Continued Examination (37 CFR 1.114) submitted herewith.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Application No.: 09/396,523

Docket No.: 22116-00005-US3


It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 22-0185, under Order No. 22116-00005-US5.

Dated: February 28, 2006

Respectfully submitted,

By


  
Burton A. Amernick

Registration No.: 24,852

CONNOLLY BOVE LODGE & HUTZ LLP

Correspondence Customer Number: 30678

Attorney for Applicant



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/396,523 Conf.# 7553
				Filing Date	September 15, 1999
				First Named Inventor	Christine L. O'Day
				Art Unit	1621
				Examiner Name	P. G. O'Sullivan
Sheet	1	of	3	Attorney Docket Number	22116-00005-US3


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author ( in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA**	Gallop, M.A., et al., "Applications of Combinatorial Technologies to Drug Discovery. Background and Peptide Combinatorial Libraries," J. MED. CHEM., (1994) 37(9): 1233-51.	
	CB**	Ganem, B., "New Chemistry of Naturally Occuring Polyamines," ACC. CHEM. RES., (1982) 15:290-8.	
	CC**	Ganem, B., et al., "Chemistry of Naturally Occurring Polyamines. II. Unsaturated Spermidine and Spermine Derivatives," J. ORG. CHEM., (1987) 52:5044-6.	
	CD**	Ganem, B., et al., "Chemistry of Naturally Occuring Polyamines. 10. Nonmetabolizable Derivatives of Spermine and Spermidine," J. ORG. CHEM., (1986) 51:4856-61.	
	CE**	Goodnow, Jr. R.A., et al., "Oligomer Synthesis and DNA/RNA Recognition Properties of a Novel Oligonucleotide Backbone Analog: Glucopyranosyl Nuclei Amide (GNA)," TETRAHEDRON LETT., (1997) 38(18):3199-3202.	
	CF**	Goodnow, Jr., R.A., et al., "Synthesis of Thymine, Cytosine, Adenine, and Guanine Containing N-Fmoc Protected Amino Acids: Building Blocks for Construction of Novel Oligonucleotide Backbone Analogs," TETRAHEDRON LETT., (1997) 38(18):3195-8.	
	CG**	Gordon, E.M., et al., "Applications of Combinatorial Technologies to Drug Discovery Combinatorial Organic Synthesis, Library Screening Strategies, and Future Directions," J. MED. CHEM., (1994) 37(10): 1385-1401.	
	CH**	Gorus, F., et al., "Applications of Bio- and Chemiluminescence in the Clinical Laboratory," CLIN. CHEM., (1979) 25(4): 512-9.	
	CI**	Han, H. et al., "Liquid-Phase Combinatorial Synthesis," PROC. NATL. ACAD. SCI. USA, (1995) 92:6419-23.	
	CJ**	Hernandez, A.S. et al., "Solid-Supported tert-Alkoxyacylation Reagents for Anchoring of Amines During Solid Phase Organic Synthesis," J. ORG. CHEM., (1997) 62:3153-7.	
	CK**	Huber, M. et al., "2,2'-Dithiobis (N-ethyl-spermine-5-carboxamide) Is a High Affinity, Membrane-Impermeant Antagonist of the Mammalian Polyamine Transport System," J. BIOL. CHEM., (1996) 271(44):27556-63.	
	CL**	Laguzza, B.C., et al., "A New Protecting Group For Amines. Synthesis of Anticapsin from L-Tyrosine," TETRAHED. LETT., (1981) 22(16):1483-6.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031


U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/396,523 Conf.# 7553
				Filing Date	September 15, 1999
				First Named Inventor	Christine L. O'Day
				Art Unit	1621
				Examiner Name	P. G. O'Sullivan
Sheet	2	of	3	Attorney Docket Number	22116-00005-US3

CM**	Lakanen, J.R., et al., "α-Methyl Polyamines: Metabolically Stable Spermidine and Spermine Mimics Capable of Supporting Growth in Cells Depleted of Polyamines," J. MED. CHEM., (1992) 35:724-34.
CN**	Lee, J., "Facile Preparation of Cyclopropylamines from Carboxamides," J. ORG. CHEM., (1997) 62:1584-5.
CO**	Li, Y. et al., "Synthesis and Antitumor Evaluation of a Highly Potent Cytotoxic DNA Cross-Linking Polyamine Analogue, 1, 12-Diaziridinyl-4, 9-diazadodecane," J. MED. CHEM., (1996) 39:339-41.
CP**	Lloyd-Williams, P., "Convergent Solid-Phase Peptide Synthesis," TETRAHEDRON, (1993) 49(48): 11065-133.
CQ**	Marton, L.J., et al., "Polyamines as Targets for Therapeutic Intervention," ANNU. REV. PHARMACOL. TOXICOL., (1995) 35:55-91.
CR**	Muramoto, K., "Preparation and Characterization of Photoactivable Heterobifunctional Fluorescent Reagents," AGRIC. BIOL. CHEM., (1984) 48 (11), 2695-9.
CS**	Nakaoka, T., et al., "Inhibition of Rat Vascular Smooth Muscle Proliferation In Vitro and In Vivo by Bone Morphogenetic Protein-2," J. CLIN. INVEST., (1997) 100 (11): 2824-32.
CT**	Pfitzner, K.E., et al., "Sulfoxide-Carbodiimide Reactions. I. A Facile Oxidation of Alcohols," J. AM. CHEM. SOC., (1965) 87(24): 5661-9.
CU**	Quemener, V., et al., "Polyamine Deprivation: A New Tool in Cancer Treatment," ANTICANCER RES., (1994) 14:443-8.
CV**	Raines, D.E., et al., "Potential-Dependent Phase Partitioning of Fluorescent Hydrophobic Ions in Phospholipid Vesicles," J.MEMBRANE BIOL., (1984) 82:241-7.
CW**	Rajeev, K.G., et al., "Conformationally Restrained Chiral Analogues of Spermine: Chemical Synthesis and Improvements in DNA Triplex Stability," J.ORG CHEM., (1997) 62:5169-73.
CX**	Ranganathan, R.S., et al., "Novel Analogs of Nucleoside 3',5'-Cyclic Phosphates. I. 5'-Mono- and Dimethyl Analogs of Adenosine 3', 5'-Cyclic Phosphate," J. ORG. CHEM., (1974) 39(3):290-8.
CY**	Rink, H., "Solid-phase synthesis of Protected Peptide Fragments Using A Trialkoxy-Diphenyl-Methylester Resin," TETRAHED. LETT., (1987) 28(33): 3787-90.
CZ**	Salemme, F.R., et al., "Serendipity Meets Precision: The Integration of Structure-Based Drug Design and Combinatorial Chemistry for Efficient Drug Discovery," STRUCTURE, (1997) 5(3):319-24.
CA1**	Sasaki, Y. et al., "Solid-Phase Synthesis and Biological Properties of Ψ[CH <sub>2</sub> NH] Pseudopeptide Analogues of a Highly Potent Somatostatin Octapeptide," J. MED. CHEM., (1987) 30(7):1162-6.
CB1**	Schallenberg, E.E., et al., "Ethyl Thioltriifluoroacetate As An Acetylating agent with Particular Reference to Peptide Synthesis," J.AM.CHEM.SOC., (1955) 77:2779-83.
CC1**	Seiler, N. et al., "Polyamine transport in Mammalian Cells. An Update," INT. J. BIOCHEM. CELL BIOL., (1996) 28(9): 843-61.
CD1**	Seiler, N. et al., "Polyamine Transport In Mammalian Cells," INT.J. BIOCHEM., (1990) 22(3):211-8.
CE1**	Shyng, S.-L., et al., "Depletion of Interacellular Polyamines Relieves Inward Rectification of Potassium Channels," PROC. NATL. ACAD. SCI. USA, (1996) 93:12014-9.
CF1**	Siegel, M.G. et al., "Rapid Purification of Small Molecule Libraries by Ion Exchange Chromatography," TETRAHEDRON LETT., (1997) 38(19): 3357-60.
CG1**	Singh, S. et al., "Characterization of Simian Malarial Parasite (Plasmodium Knowlesi) -induced Putrescine Transport in Rhesus Monkey Erythrocytes," J. BIOL. CHEM., (1997) 272(21): 13506-11.
CH1**	Thompson, L.A. et al., "Straightforward and General Method for Coupling Alcohols to Solid Supports," TETRAHED. LETT., (1994) 35:9333-6.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				<b>Complete if Known</b>	
				Application Number	09/396,523 Conf.# 7553
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Filing Date	September 15, 1999
				First Named Inventor	Christine L. O'Day
				Art Unit	1621
				Examiner Name	P. G. O'Sullivan
				Attorney Docket Number	22116-00005-US3
Sheet	3	of	3		

	CI1**	Ventura, C. et al., "Polyamine Effects on [Ca <sup>2+</sup> ] Homeostasis and Contractility in Isolated Rat Ventricular Cardiomyocytes," AM. J. PHYSIOL., (1994) 267:H587-H592.	
	CJ1**	Wang, S.-S., "p-Alkoxybenzyl Alcohol Resin and p-Alkoxybenzyloxycarbonylhydrazide Resin for Solid Phase Synthesis of Protected Peptide Fragments," J. AM. CHEM. SOC., (1973) 95(4): 1128-1333.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--